搜索结果
靶点ID:TCMBANKGE007589
靶点别名:ATP5B; ATPMB; ATPSB; HEL-S-271
靶点描述:ATP synthase F1 subunit beta
染色体:12
染色体位置:12q13.3
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:830
OMIM_Link:102910
Ensembl_Link:ENSG00000110955
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN024528 | l-pipecolinic acid | C6H11NO2 | 129.16 g/mol | C1CCNC(C1)C(=O)O | |
| TCMBANKIN036067 | vanadium | V | 50.941 g/mol | [V] | |
| TCMBANKIN038032 | formononetin | Oprea1_815287; AIDS027672; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one; Isoflavone, 7-hydroxy-4'-methoxy- (8CI); NCI60_042081; NCGC00095207-03; Oprea1_139748; NCIOpen2_005983; SDCCGMLS-0066428.P001; CHEBI:18088; TNP00176; 485-72-3; Formononetol; Isoflavone, 7-hydroxy-4'-methoxy-; 7-hydroxy-3-(4-methoxyphenyl)chromone; Spectrum2_000560; Formononetin; NSC 93360; EINECS 207-623-9; 47752_FLUKA; KBio2_000853; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; Spectrum5_000258; KBio3_001519; NSC93360; KBioSS_000853; Spectrum_000373; SPECTRUM102007; KBio2_005989; Biochanin B; KBioGR_001878; NCGC00017269-01; 7-Hydroxy-3-(4′-methoxyphenyl)-4H-benzopyran-4-one; formononetin ; 7-hydroxy-4'-methoxy-isoflavone; BSPBio_002299; ZINC00113304; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)- (9CI); SBB016445; Spectrum3_000660; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Spectrum4_001429; DivK1c_006319; KBio2_003421; SPBio_000639; NCGC00095207-01; KBio1_001263; AIDS-027672; 7-Hydroxy-4'-methoxyisoflavone; C00858; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; NCGC00095207-02; SpecPlus_000223 | C16H12O4 | 268.264 | C1([H])=C(c2c([H])c([H])c(OC([H])([H])[H])c([H])c2[H])C(c3c(O1)c([H])c(O[H])c([H])c3[H])=O |
| TCMBANKIN057899 | arsenicum;arsenic;as | As | 74.92159 g/mol | [As] | |
| TCMBANKIN058122 | piceatannol | (e)-piceatannol; NCGC00015794-01; 5-[(Z)-2-(3,4-dihydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(Z)-2-(3,4-dihydroxyphenyl)vinyl]benzene-1,3-diol; Lopac-P-0453; PIT; e-piceatannol; (e)-piceatannol; 5-[(Z)-2-(3,4-dihydroxyphenyl)vinyl]resorcinol; NCGC00094226-05; 5-[(E)-2-(3,4-dihydroxyphenyl)vinyl]resorcinol; KBio3_000859; IDI1_002155; 3,3',4,5'-Tetrahydroxystilbene; 3,3',4,5'-Stilbenetetrol; C05901; EU-0100915; NSC 622471; 1,2-Benzenediol, 4-[2-(3,5-dihydroxyphenyl)ethenyl]-, (E)-; 3,3',4'5-Tetrahydroxystilbene; 5-[2-(3,4-dihydroxyphenyl)ethenyl]benzene-1,3-diol; NSC365798; Lopac0_000915; 5-[2-(3,4-dihydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(3,4-dihydroxyphenyl)vinyl]resorcinol; MEGxp0_000245; KBio2_000460; SMP2_000263; trans-3,3′,4,5′-Tetrahydroxystilbene; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-; 21100-92-5; trans-3,3',4,5'-Tetrahydroxystilbene; 5-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]benzene-1,3-diol; AIDS-160223; (E)-4-[2-(3,5Dihydroxyphenyl)ethenyl]1,2-benzenediol; Piceatannol; NSC 365798; 4339-71-3; E-Piceatannol; 3-Hydroxyresveratol; 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; KBio2_005596; 10083-24-6; NCGC00094226-04; BiomolKI2_000031; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; KBioGR_000460; Bio2_000880; KBioSS_000460; NSC622471; KBio2_003028; 5-[(E)-2-(3,4-dihydroxyphenyl)vinyl]benzene-1,3-diol; KBio3_000860; 3,5,3',4'-Tetrahydroxystilbene; 1,2-Benzenediol, {4-[2-(3,} 5-dihydroxyphenyl)ethenyl]-, (E)-; BSPBio_001120; NCGC00094226-02; NCI60_003368; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-, (E)-; Astringinine; P0453_SIGMA; BiomolKI_000023; AIDS160223; CHEBI:28814; 4-(2-(3,5-Dihydroxyphenyl)vinyl)-1,2-benzenediol; Bio2_000400; 3,3′,4,5′-Tetrahydroxy-trans-stilbene; K00089; ZINC00014036 | C14H12O4 | 244.24 g/mol | C1=CC(=C(C=C1C=CC2=CC(=CC(=C2)O)O)O)O |
| TCMBANKIN058205 | trans-resveratrol | (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene | C14H12O3 | 228.24 g/mol | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
| TCMBANKIN058267 | vitamin b | NSC169454; SR-01000722017-4; Nicotinic acid, >=98%; [3H]nicotinic acid; Nicotinamide (JP15/INN); AC1Q73P3; C6H5NO2; 11054-EP2289510A1; NCGC00094734-02; AB00052050; HMS3655K08; Efacin; Nico-400; N1103; 11054-EP2298772A1; TR-032523; C00253; Nicosan 3; SPBio_000011; Nicotinic Acid [Matrix for MALDI-TOF/MS]; SPBio_002881; 5-22-02-00057 (Beilstein Handbook Reference); Niacinamide Astra Brand; Spectrum3_000515; ANW-75276; Bionic; 11054-EP2301923A1; SDCCGMLS-0066610.P001; Nicotinsaure [German]; Nicotinic acid, >=99.5% (HPLC); preventative factor; 28029-53-0 (cobalt(2+) salt); SR-01000722017-3; Acide nicotinique [INN-French]; 11054-EP2295409A1; NICO; InChI=1/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9; D00049; Jenapharm Brand of Niacinamide; Nicotinamide (TN); Niacin [USAN]; bmse000104; 1976-28-9 (aluminum salt); 11054-EP2311816A1; Apelagrin; AN-23622; KBio2_001543; ABT-919; Acido nicotinico; .beta.-Pyridinecarboxylic acid; Niaspan (TN); 11054-EP2270002A1; SR-01000722017-2; KB-33243; Pellagramin; NCGC00016268-02; DSSTox_CID_932; Merck Brand of Niacinamide; nicobid; beta-pyridinecarboxylic acid; BDBM23515; 3PyrCOOH; Nicotinic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=98%; Pellagra preventive factor; niacin; Prestwick0_000881; Nicotinic acid, Ph Eur; BPBio1_000730; Nicacid; UNII-2679MF687A; EBD2198325; NCGC00016268-08; 3-Carboxypyridine; ST097540; Z56755709; Davitamon PP; Nicotinamide (Niacinamide); Nicotinic acid, analytical standard; CPD000059024; 3-Pyridylcarboxylic acid; Pyridine-beta-carboxylic acid; KBioSS_001543; 11054-EP2305674A1; Nicotinic acid, for synthesis, 99%; Nicodon; Oprea1_514398; [5, 6-3H]-niacin; 636-79-3 (hydrochloride); Direktan; Niacin (Nicotinic Acid), Pharmaceutical Secondary Standard; Certified Reference Material; DB-007765; 11054-EP2298742A1; Nyclin; 11054-EP2316827A1; NSC-169454; 7069-06-9 (magnesium salt); 11054-EP2316826A1; Niacor; niacine; MLS000069603; AC-907/25014105; GTPL1594; Spectrum5_001287; RP00705; niacin potassium; BSPBio_002069; STR00112; IDI1_000695; LS-2334; AM81316; NAH; P.P. factor-pellagra preventive factor; AC-22484; Vitaplex N; Nicodan; 3789-96-6 (tartrate); 11054-EP2311829A1; AB1002056; Niacinamide Merck Brand; Spectrum4_000965; Pyridinecarboxylic acid, 3-; CCRIS 1902; 11054-EP2308838A1; SBI-0051456.P003; 11054-EP2280001A1; Nicotinic acid [INN]; PubChem2594; Nicovasen; 54-86-4 (hydrochloride salt); 11054-EP2274983A1; 11054-EP2308854A1; NCGC00016268-04; MCULE-3788394698; Nicagin; nicolar; NIASPAN TITRATION STARTER PACK; AB00052050-13; ST2413625; J-523605; 36321-41-2 (ammonium salt); Acido nicotinico [INN-Spanish]; Akotin; EINECS 200-441-0; SBB004279; 11054-EP2311830A1; Niacin, United States Pharmacopeia (USP) Reference Standard; Acidum nicotinicum; Nikasan; SR-01000722017; AK-46486; Enduracin; CS-1946; Nicotinic acid, certified reference material, TraceCERT(R); Induracin; Nico-Span; antipellagra vitamin; 3-pyridine carboxylic acid; Nicoside; Nicotinic acid, purum, >=99.0% (HPLC); CHEMBL573; Pyridylcarboxylic Acid; Tinic; 11054-EP2295424A1; EPA Pesticide Chemical Code 056701; Nicotine acid; Ncotnc acd; 11054-EP2305651A1; pellagra; Nicorol; 5-pyridinecarboxylic acid; NCGC00094734-01; 11054-EP2298776A1; 3-Picolinic acid; Niacin; Pellagra preventive factor; Pyridine-3-carboxylic acid; Vitamin B3; KBioGR_001309; 11054-EP2308848A1; KSC236Q9T; Nipellen; Niacin (USP); 3-pyridinecarboxylic acid; Vitamin B3 (Niacin); KBio2_006679; NCI60_001041; HMS2236A05; AB00052050_14; Nicotinic acid, matrix substance for MALDI-MS, >=99.5% (HPLC); HMS2097B04; Spectrum2_000006; 99148-57-9 (tosylate); SCHEMBL1433; BSPBio_000662; MolPort-000-142-273; KBio3_001569; 10361-13-4 (iron(2+) salt); Tox21_110337_1; F2191-0082; Acide nicotinique; Nicotinic acid, European Pharmacopoeia (EP) Reference Standard; 11054-EP2269990A1; 11054-EP2308858A1; M-5918; 11054-EP2275401A1; Nicotinic acid, plant cell culture tested; Nicotinic acid, SAJ special grade, >=99.5%; Niacinamide (TN); HMS3714B04; STK301803; Pelonin; Niconazid; Prestwick2_000881; Nicovasan; 11054-EP2270014A1; Niacinamide Pharmagenix Brand; Pharmakon1600-01500430; Pyridine-carboxylique-3 [French]; SK-Niacin; Prestwick1_000881; Nikazan; EC 200-441-0; PP Factor; AKOS000118980; HY-B0143; Tox21_110337; HMS3371E07; WLN: T6NJ CVQ; Nicotene; Nicotinic acid [INN:BAN]; CAS-59-67-6; 11054-EP2316458A1; Kyselina nikotinova [Czech]; P.P. factor; Pyridine-3-carboxylic acid; Niacin (nicotinic acid); Tox21_201420; L001199; NCGC00016268-09; nicocap; I02-0699; nicotinic acid; Niconat; ZINC1795; Niacin [USP]; Diacin; 11054-EP2272825A2; Kyselina nikotinova; FC1287; Nicotinic acid-d3(major); CHEBI:15940; 823-77-8 (calcium salt); Niacor (TN); DSSTox_RID_75875; NCGC00256537-01; Nicotamin; GTPL1588; 2679MF687A; ACMC-1AS6M; [3H]-Nicotinic acid; SPECTRUM1500430; Acidum nicotinicum [INN-Latin]; HMS1570B04; 11054-EP2301937A1; KBio1_000695; BP-21419; Niacinamide Jenapharm Brand; AJ-08093; Nicotinic acid, NIST(R) SRM(R) 148; niacin magnesium; Nicyl; S115; Tega-Span; 11054-EP2269610A2; KBio2_004111; AC1L1AD5; NCGC00016268-01; Niacinamide, Nicotinic acid amide, Nicotinamide; Opera_ID_1346; Nicotinic acid, 99% 250g; 3-Pyridyl carboxylic acid; Nicocidin; nicotinate; s1744; SR 4390; DTXSID1020932; Nicotinsaure; 16518-17-5 (potassium salt); Nicotinic acid, Vetec(TM) reagent grade, >=98%; 11054-EP2308839A1; Linic; BIDD:GT0644; NC00524; wampocap; NCGC00016268-03; Nicotinic acid, for inorganic trace analysis, >=99.999% (metals basis); AB00052050_15; Nicosyl; CCG-38340; D06NVJ; 11054-EP2301935A1; 11054-EP2308874A1; Nikotinsaeure; SC-05611; Pyridine-3-carbonic acid; Nicodelmine; 53890-72-5 (lithium salt); 11054-EP2311808A1; SMR000059024; Daskil; NSC 169454; MFCD00006391; PS-4255; HMS502C17; 11054-EP2272848A1; FT-0082580; Pyridine-.beta.-carboxylic acid; DivK1c_000695; 11054-EP2295406A1; Niacin-Vitamin B3; N0082; BRN 0109591; 3-Carboxylpyridine; 11054-EP2316828A1; Niac; NCGC00258971-01; 3-Picolinic acid; 11054-EP2292610A1; NINDS_000695; 11054-EP2292228A1; FT-0600004; Astra Brand of Niacinamide; Nicotinic Acid 1.0 mg/ml in Methanol; 11054-EP2272834A1; HMS3259K21; Niacin (TN); Nicotinic acid (JP17/INN); NSC-757241; Prestwick3_000881; Niaspan; Slo-niacin; SAM002554917; HMS2091H22; Pharmagenix Brand of Niacinamide; 59-67-6; NCGC00016268-05; Tox21_302904; Pellagrin; Caswell No. 598; 11054-EP2277848A1; 3DDB011E-F3A6-45B6-A2D2-77B2A6E8936E; 11054-EP2301929A1; 11054-EP2311817A1; Naotin; m-Pyridinecarboxylic acid; vitamin B3; HSDB 3134; Peviton; nicamin; Nicotinic acid (Vitamin B3) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Nicangin; Spectrum_001063; Pyridine-carboxylique-3; KB-259513; 11054-EP2298779A1; Nicocrisina; DB00627; 11054-EP2316825A1; AI3-18994; PVNIIMVLHYAWGP-UHFFFAOYSA-N; 11054-EP2316457A1; I14-92791; anti-Pellagra vitamin; 28029-54-1 (manganese(2+) salt); NSC757241; 123574-58-3; Nicotil; HMS1920P17; Nicotinipca; 3-Pyridinecarboxylicacid; 11054-EP2314588A1; Niconacid; NIO; Nicotinic acid, meets USP testing specifications; DSSTox_GSID_20932; Nicotinamide-carbonyl-14C | C5H4NCOOH | 123.11 g/mol | C1=CC(=CN=C1)C(=O)O |
| TCMBANKIN059452 | ethyl aldehyde | C2H4O | 44.05 g/mol | CC=O | |
| TCMBANKIN059684 | Vitamin E β- | C29H50O2 | 430.79 | CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O | |
| TCMBANKIN059746 | α-tocopherol | C29H50O2 | 430.7 g/mol | CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
滇IICP备16009434号-1 |
Dai SX Lab